Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Cost of goods sold | 282.7 | 279.4 |
| Gross profit | 309.4 | 306.0 |
| Selling, general and administrative expense | 212.4 | 208.8 |
| Research and development expense | 62.9 | 73.5 |
| Income from operations | 34.1 | 23.7 |
| Interest expense | 12.3 | 12.0 |
| Foreign currency exchange gains, net | (2.4) | (2.7) |
| (Gains) losses from change in fair market value of equity securities and loan receivable | 738.2 | (31.8) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bio-Rad Laboratories's R&D?
- Bio-Rad Laboratories (BIO) reported R&D of $62.9M in Q1 2026.
- How has Bio-Rad Laboratories's R&D changed year-over-year?
- Bio-Rad Laboratories's R&D decreased by 14.4% year-over-year, from $73.5M to $62.9M.
- What is the long-term trend for Bio-Rad Laboratories's R&D?
- Over 4 years (2021 to 2025), Bio-Rad Laboratories's R&D has grown at a 1.4% compound annual growth rate (CAGR), from $260.64M to $275.6M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Bio-Rad Laboratories's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude